Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07859462 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase I Study of In Vivo CAR-Tumor Technology for the Treatment of Advanced Malignant Tumors

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a single-arm, open-label, dose-escalation platform clinical trial designed to evaluate the safety, tolerability, efficacy, pharmacokinetic and pharmacodynamic characteristics of CAR-Tumour oncolytic virus as a vector platform for the treatment of advanced malignant tumours. Subjects will be screened and assigned to cohorts based on target and indication: Cohort A: Intratumoural injection or intravenous injection of CAR-Tumor05 solution for the treatment of advanced malignant solid tumours Co-group B: Intratumoural injection, intravenous injection, subcutaneous injection, intramuscular injection, pleural perfusion, and intraperitoneal perfusion of CAR-Tumor05 injection for the treatment of advanced malignant solid tumours Co-group C: Intratumoural injection, intravenous injection, subcutaneous injection, intramuscular injection, pleural perfusion, and intraperitoneal perfusion of CAR-Tumor M01 injection for the treatment of advanced malignant solid tumours
Trial Details
NCT Number NCT07859462
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborators: Joint Biosciences Ltd.
Conditions Advanced Solid Tumor
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov